Sangwan N, Gangwal A, Jain P, Langtso C, Srivastava S, Dhawan U
Toxins (Basel). 2025; 17(2).
PMID: 39998073
PMC: 11860322.
DOI: 10.3390/toxins17020056.
Wu L, Chen Y, Yan Y, Wang H, Guy C, Carney J
Toxins (Basel). 2025; 17(2).
PMID: 39998071
PMC: 11861023.
DOI: 10.3390/toxins17020054.
Turcotte E, Kim K, Eislmayr K, Goers L, Mitchell P, Lesser C
bioRxiv. 2025; .
PMID: 39975412
PMC: 11838452.
DOI: 10.1101/2025.02.01.636075.
Wang Y, Bai M, Peng Q, Li L, Tian F, Guo Y
Eur J Med Res. 2024; 29(1):614.
PMID: 39710789
PMC: 11664877.
DOI: 10.1186/s40001-024-02224-5.
Liu J, Zuo Z, Fattah R, Finkel T, Leppla S, Liu S
mBio. 2024; 15(12):e0216024.
PMID: 39508614
PMC: 11633152.
DOI: 10.1128/mbio.02160-24.
Alpha-1 antitrypsin inhibits Clostridium botulinum C2 toxin, Corynebacterium diphtheriae diphtheria toxin and B. anthracis fusion toxin.
Lietz S, Sokolowski L, Barth H, Ernst K
Sci Rep. 2024; 14(1):21257.
PMID: 39261531
PMC: 11390955.
DOI: 10.1038/s41598-024-71706-7.
Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study.
da Fonseca I, Nagamine M, Gentile L, Nishiya A, da Fonseca J, de Oliveira Massoco C
Vet Res Commun. 2024; 48(4):2407-2428.
PMID: 38805149
DOI: 10.1007/s11259-024-10400-5.
Dachshund Homolog 1: Unveiling Its Potential Role in Megakaryopoiesis and Lethal Toxin-Induced Thrombocytopenia.
Lin G, Chang H, Lin W, Liou Y, Lai Y, Hsieh M
Int J Mol Sci. 2024; 25(6).
PMID: 38542074
PMC: 10970148.
DOI: 10.3390/ijms25063102.
Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?.
Tessier E, Cheutin L, Garnier A, Vigne C, Tournier J, Rougeaux C
Microorganisms. 2024; 12(2).
PMID: 38399712
PMC: 10891819.
DOI: 10.3390/microorganisms12020308.
, "la maladie du charbon", Toxins, and Institut Pasteur.
Goossens P
Toxins (Basel). 2024; 16(2).
PMID: 38393144
PMC: 10891547.
DOI: 10.3390/toxins16020066.
Anthrax lethal toxin and tumor necrosis factor-α synergize on intestinal epithelia to induce mouse death.
Gao X, Teng T, Liu Y, Ai T, Zhao R, Fu Y
Protein Cell. 2023; 15(2):135-148.
PMID: 37855658
PMC: 10833652.
DOI: 10.1093/procel/pwad050.
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics.
Ouyang W, Xie T, Fang H, Frucht D
Toxins (Basel). 2023; 15(9).
PMID: 37755954
PMC: 10538138.
DOI: 10.3390/toxins15090528.
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.
Ruschig M, Marschall A
BioDrugs. 2023; 37(2):181-203.
PMID: 36729328
PMC: 9893211.
DOI: 10.1007/s40259-023-00580-y.
Comprehensive characterization of toxins during progression of inhalation anthrax in a non-human primate model.
Boyer A, Gallegos-Candela M, Lins R, Solano M, Woolfitt A, Lee J
PLoS Pathog. 2022; 18(12):e1010735.
PMID: 36534695
PMC: 9810172.
DOI: 10.1371/journal.ppat.1010735.
The subversion of toll-like receptor signaling by bacterial and viral proteases during the development of infectious diseases.
Ciaston I, Dobosz E, Potempa J, Koziel J
Mol Aspects Med. 2022; 88:101143.
PMID: 36152458
PMC: 9924004.
DOI: 10.1016/j.mam.2022.101143.
Treatment of ovarian cancer with modified anthrax toxin.
Aktories K
Proc Natl Acad Sci U S A. 2022; 119(32):e2210179119.
PMID: 35917343
PMC: 9371659.
DOI: 10.1073/pnas.2210179119.
A potent tumor-selective ERK pathway inactivator with high therapeutic index.
Zuo Z, Liu J, Sun Z, Silverstein R, Zou M, Finkel T
PNAS Nexus. 2022; 1(3):pgac104.
PMID: 35899070
PMC: 9308561.
DOI: 10.1093/pnasnexus/pgac104.
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.
Duru N, Pawar N, Martin E, Buzza M, Conway G, Lapidus R
Proc Natl Acad Sci U S A. 2022; 119(28):e2201423119.
PMID: 35867758
PMC: 9282395.
DOI: 10.1073/pnas.2201423119.
Bacterial Toxin and Effector Regulation of Intestinal Immune Signaling.
Woida P, Satchell K
Front Cell Dev Biol. 2022; 10():837691.
PMID: 35252199
PMC: 8888934.
DOI: 10.3389/fcell.2022.837691.
Innate Sensors Trigger Regulated Cell Death to Combat Intracellular Infection.
Nozaki K, Li L, Miao E
Annu Rev Immunol. 2022; 40:469-498.
PMID: 35138947
PMC: 9614550.
DOI: 10.1146/annurev-immunol-101320-011235.